• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

    7/18/24 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email

    ‘Breaking Barriers' Coalition Formed to Address Opioid Use Disorder in the USA

    Nexalin CEO Mark White Participates in Inaugural Meeting

    HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced that it has been selected to serve as a founding member of Breaking Barriers to Substance Use Recovery, a coalition of major industry participants and preeminent healthcare providers.

    Established as a tax-exempt organization, Breaking Barriers to Substance Use Recovery is focused on identifying and dismantling the obstacles to effective treatment for opioid use disorder. Breaking Barriers to Substance Use Recovery brings together bringing together a broad cross section of leaders in the medical and science and technology industries to develop and formulate pioneering and innovative solutions to combat the opioid crisis. The organization also advocates for the adoption of comprehensive policy solutions in support of its critical life-saving objectives and raises public awareness through education campaigns.

    Breaking Barriers to Substance Use Recovery is a pioneering 501(c)(4) organization dedicated to identifying and dismantling the obstacles to effective treatment for opioid use disorder through advocacy, especially in veteran and rural communities across the United States, for policy solutions and public educational campaigns that support these critical life-saving objectives.

    Nexalin anticipates partnering with the organization in deploying its neurostimulation technologies for the purpose of furthering the objectives of providing an accessible and innovative form of treatment for those in-need and swept up by the current pervasive epidemic. Nexalin also hopes to promote and strengthen the engagement of the organization with U.S. government agencies tasked with addressing the ongoing opioid crisis.

    Mark White, CEO of Nexalin, participated in the inaugural founding meeting of Breaking Barriers to Substance Use Recovery, hosted in Washington D.C. at the end of June in 2024.

    The organization's other founding members took part in the meeting, and include:

    • Peter Gratale, founder of Breaking Barriers to Substance Use Recovery
    • Franklin Walker, VP of the NC Medical Society Foundation
    • David Reeser, CEO of OpiAID, Inc.
    • Reynold Yordy, CTO of The Recovery Platform, LLC
    • John Hsu, MD, Co-Founder of IPill, Inc.
    • Keivan Ettefagh, PhD, VP of Technology and Innovation, Select Lab Partners, Inc.

    The meeting featured discussions on the latest research, treatment methodologies, and technological advancements in the field, as well as an in-depth policy analysis of transformational ongoing legislative opportunities that seek to expand access to opioid treatment.

    "Today marks a crucial step in our journey to combat opioid addiction," said Peter Gratale. "Our collective expertise and commitment will drive us to uncover the root causes of barriers to treatment and to promote policies and practices that support recovery and save lives."

    "We are honored to join the Breaking Barriers to Substance Use Recovery initiative to help solve the very important substance use addiction problem affecting over 20 million of people in the U.S. alone," stated Mark White, CEO of Nexalin Technology. "This partnership signals a growing acknowledgment of the crucial role that our innovative neurostimulation technologies can play to effectively treat patients with mental health diseases in a pain-free and undetectable manner. We look forward to working with fellow players in the healthcare industry to lead the way towards tackling the global opioid epidemic." 

    Organization's Advocacy for Virtual-Based Opioid Treatment

    A key focus of Breaking Barriers to Substance Use Recovery includes advocacy for 21st century solutions to the opioid crisis, including an expansion of Virtual-Based Opioid Treatment (VBOT), a tested treatment model that can dramatically combat traditional barriers to treatment. The organization endeavors to create a model utilizing innovative virtual technologies and services, providing more accessible, cost-effective, and comprehensive care options for those struggling with opioid use disorder (OUD), especially veterans and those in rural areas. Breaking Barriers looks to also advocate for emerging technologies and therapeutic techniques that can be coupled with VBOT while harnessing AI and data-driven methodologies that provide new insights into treatment success and compliance.

    "VBOT offers a revolutionary approach to overcoming barriers such as geographic limitations and stigma," said David Reeser, CEO of OpiAID, Inc. "Our goal is to harness these technologies to ensure everyone has access to the help they need, regardless of their circumstances."

    As Breaking Barriers to Substance Use Recovery moves forward, the organization plans to engage nationwide with policymakers, healthcare providers, and community leaders to implement evidence-based solutions and advocate for necessary changes in legislation and healthcare practices.

    For more information about Breaking Barriers to Substance Use Recovery and its initiatives, please contact:

    Breaking Barriers to Substance Use Recovery

    12 North 5th Avenue 

    Wilmington, NC 28401

    Phone: (xxx) xxx-1234 

    Email: [email protected] 

    Website: [www.nomorebarriers.org]

    About Nexalin Technology, Inc.

    Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

    FORWARD-LOOKING STATEMENTS

    This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website,
    www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

    Contact:

    Crescendo Communications, LLC

    Tel: (212) 671-1020

    Email: [email protected]



    Primary Logo

    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/5/25 3:17:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/4/25 5:05:25 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

      HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will detail the Company's growing body of clinical evidence, including collaborations with leading institutions like UC San Diego, and share updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model—designed for scalable, at-home treatment. With regulatory approvals secured interna

      5/28/25 10:00:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

      HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) --  Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. Maxim Group LLC acted as sole book-running manager for the offering. The public offering was made pursuant to an effective shelf registration statement on Form S-3

      5/6/25 2:40:23 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Financials

    Live finance-specific insights

    See more
    • LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T

      11/1/24 9:00:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

      10/25/24 9:00:00 AM ET
      $CLDI
      $NXL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and LOBO EV Technologies Ltd. (NASDAQ:LOBO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessLOBO EV: https://www.redchip.com/assets/access/lobo_accessMark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of th

      7/26/24 9:55:00 AM ET
      $LOBO
      $NXL
      Motor Vehicles
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by President and CEO White Mark

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:34:13 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Owens David

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:33:38 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    Leadership Updates

    Live Leadership Updates

    See more
    • Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

      HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin's strategic prioritization of Alzheimer's disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS™ technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, e

      5/13/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

      HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company'

      2/26/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

      HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") announces the appointment of Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. With more than 30 years of experience in the medical device industry, Shelton brings a wealth of knowledge in regulatory compliance, quality assurance, and clinical development. In her role, she will oversee all clinical studies, quality systems, and regulatory submissions, ensuring Nexalin's commitment to innovation, safety, and excellence as the Company prepares to pursue global regulatory clearances and future FDA Breakthrough Device designations for its

      10/14/24 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NXL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nexalin Technology Inc.

      10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

      5/13/25 3:31:04 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 12:39:21 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 424B4 filed by Nexalin Technology Inc.

      424B4 - Nexalin Technology, Inc. (0001527352) (Filer)

      5/6/25 11:44:26 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care